Epigral Limited (EPIGRAL.NS)
- Previous Close
1,762.90 - Open
1,730.10 - Bid 1,738.60 x --
- Ask 1,740.00 x --
- Day's Range
1,708.00 - 1,768.00 - 52 Week Range
1,110.05 - 2,406.75 - Volume
31,225 - Avg. Volume
57,994 - Market Cap (intraday)
74.971B - Beta (5Y Monthly) --
- PE Ratio (TTM)
20.54 - EPS (TTM)
84.62 - Earnings Date --
- Forward Dividend & Yield 7.50 (0.43%)
- Ex-Dividend Date Feb 7, 2025
- 1y Target Est
2,450.00
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash products. It also engages in the trading of agrochemical products. It serves various sectors, including CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.
www.epigral.comRecent News: EPIGRAL.NS
View MorePerformance Overview: EPIGRAL.NS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EPIGRAL.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EPIGRAL.NS
View MoreValuation Measures
Market Cap
76.05B
Enterprise Value
80.59B
Trailing P/E
20.82
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.92
Price/Book (mrq)
3.99
Enterprise Value/Revenue
3.16
Enterprise Value/EBITDA
11.09
Financial Highlights
Profitability and Income Statement
Profit Margin
13.94%
Return on Assets (ttm)
12.47%
Return on Equity (ttm)
22.65%
Revenue (ttm)
25.65B
Net Income Avi to Common (ttm)
3.58B
Diluted EPS (ttm)
84.62
Balance Sheet and Cash Flow
Total Cash (mrq)
22.19B
Total Debt/Equity (mrq)
31.11%
Levered Free Cash Flow (ttm)
876.07M